Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil Poulter

Showing results (11-20 of 179) with videos related to

Pageof 18
Sort By:
Hypertension (Dallas, Tex. : 1979)|May 28, 2009
Implementation of pay for performance policy in EnglandEmanuela Falaschetti, Norm R C Campbell, Sailesh Mohan, et al.
Health Technology Assessment (Winchester, England)|August 5, 2016
An evaluation of the effect of an angiotensin-converting enzyme inhibitor on the growth rate of small abdominal aortic aneurysms: a randomised placebo-controlled trial (AARDVARK)Gaia Kiru, Colin Bicknell, Emanuela Falaschetti, et al.
Clinical Endocrinology|May 18, 2011
Improving lipid profiles and increasing use of lipid-lowering therapy in England: results from a national cross-sectional survey - 2006Jennifer Mindell, Maria Aresu, Paola Zaninotto, et al.
Canadian Pharmacists Journal : CPJ = Revue Des Pharmaciens Du Canada : RPC|January 27, 2025
Community pharmacy-based hypertension screening: May Measurement Month 2023 in 3 Canadian provincesStephanie C Gysel, Tiffany A Lee, Neil Poulter, et al.
Pharmacoepidemiology and Drug Safety|September 5, 2019
Effectiveness of two-drug therapy versus monotherapy as initial regimen in hypertension: A propensity score-matched cohort study in the UK Clinical Practice Research DatalinkKarine Marinier, Pauline Macouillard, Martine de Champvallins, et al.
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|November 4, 2006
Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers. A mini-symposium held at the British Hypertension Society Meeting, September 2005Neil Poulter, Alan D Hughes, Bryan Williams, et al.
Medicine|May 19, 2025
Insights from the 2023 May measurement month campaign in Newfoundland and Labrador, Canada: A cross-sectional studyStephen D Coombs, Ross T Tsuyuki, Stephanie W Young, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|December 14, 2006
Utility loss and indirect costs following cardiovascular events in hypertensive patients: the ASCOT health economic substudyPeter Lindgren, Thomas Kahan, Neil Poulter, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 23, 2016
Changes in Quality of Life Associated with Complications of Diabetes: Results from the ADVANCE StudyAlison Hayes, Hisatomi Arima, Mark Woodward, et al.
Journal of Hypertension|January 27, 2011
Issues in the development of new combinations of blood pressure lowering drugsJohn Chalmers, Stephen Harrap, Krzysztof Narkiewicz, et al.
Pageof 18

Showing results (11-20 of 179) with videos related to

Sort By:
Pageof 18
Hypertension (Dallas, Tex. : 1979)|May 28, 2009
Implementation of pay for performance policy in EnglandEmanuela Falaschetti, Norm R C Campbell, Sailesh Mohan, et al.
Health Technology Assessment (Winchester, England)|August 5, 2016
An evaluation of the effect of an angiotensin-converting enzyme inhibitor on the growth rate of small abdominal aortic aneurysms: a randomised placebo-controlled trial (AARDVARK)Gaia Kiru, Colin Bicknell, Emanuela Falaschetti, et al.
Clinical Endocrinology|May 18, 2011
Improving lipid profiles and increasing use of lipid-lowering therapy in England: results from a national cross-sectional survey - 2006Jennifer Mindell, Maria Aresu, Paola Zaninotto, et al.
Canadian Pharmacists Journal : CPJ = Revue Des Pharmaciens Du Canada : RPC|January 27, 2025
Community pharmacy-based hypertension screening: May Measurement Month 2023 in 3 Canadian provincesStephanie C Gysel, Tiffany A Lee, Neil Poulter, et al.
Pharmacoepidemiology and Drug Safety|September 5, 2019
Effectiveness of two-drug therapy versus monotherapy as initial regimen in hypertension: A propensity score-matched cohort study in the UK Clinical Practice Research DatalinkKarine Marinier, Pauline Macouillard, Martine de Champvallins, et al.
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|November 4, 2006
Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers. A mini-symposium held at the British Hypertension Society Meeting, September 2005Neil Poulter, Alan D Hughes, Bryan Williams, et al.
Medicine|May 19, 2025
Insights from the 2023 May measurement month campaign in Newfoundland and Labrador, Canada: A cross-sectional studyStephen D Coombs, Ross T Tsuyuki, Stephanie W Young, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|December 14, 2006
Utility loss and indirect costs following cardiovascular events in hypertensive patients: the ASCOT health economic substudyPeter Lindgren, Thomas Kahan, Neil Poulter, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 23, 2016
Changes in Quality of Life Associated with Complications of Diabetes: Results from the ADVANCE StudyAlison Hayes, Hisatomi Arima, Mark Woodward, et al.
Journal of Hypertension|January 27, 2011
Issues in the development of new combinations of blood pressure lowering drugsJohn Chalmers, Stephen Harrap, Krzysztof Narkiewicz, et al.
Pageof 18